Ultrasound - Nuchal Translucency

Embryology - 26 Apr 2024        Expand to Translate
Google Translate - select your language from the list shown below (this will open a new external page)
العربية | català | 中文 | 中國傳統的 | français | Deutsche | עִברִית | हिंदी | bahasa Indonesia | italiano | 日本語 | 한국어 | မြန်မာ | Pilipino | Polskie | português | ਪੰਜਾਬੀ ਦੇ | Română | русский | Español | Swahili | Svensk | ไทย | Türkçe | اردو | ייִדיש | Tiếng Việt    These external translations are automated and may not be accurate. (More? About Translations)

Introduction

File:Ultrasound nuchal translucency

Ultrasound Imaging planes

Nuchal translucency (NT) is the normal fluid-filled subcutaneous space that can be measured by ultrasound imaging between GA week 11 to 14 and is used as a diagnostic "soft marker", a measured increase in this space can relate to Trisomy 21 and other neural and chromosomal conditions in the fetus.

The term "soft markers" refers to ultrasound measurements which may not be diagnostic by themselves, but can have an indicative role for further diagnostic analysis of the pregnancy.

The Diagnostic Imaging Committee of the Society of Obstetricians and Gynaecologists of Canada in 2005 made the following recommendations:

1. The screening ultrasound at 16 to 20 weeks should evaluate 8 markers, 5 of which (thickened nuchal fold, echogenic bowel, mild ventriculomegaly, echogenic focus in the heart, and choroid plexus cyst) are associated with an increased risk of fetal aneuploidy, and in some cases with nonchromosomal problems, while 3 (single umbilical artery, enlarged cisterna magna, and pyelectasis) are only associated with an increased risk of nonchromosomal abnormalities when seen in isolation (II-2 B).
2. Identification of soft markers for fetal aneuploidy requires correlation with other risk factors, including history, maternal age, and maternal serum testing results (II-1 A).
3. Soft markers identify a significant increase in fetal risk for genetic disease. Timely referral for confirmation, counselling, and investigation is required to maximize management options (III-B).

Ultrasound can also be used in combination with other techniques to locate both embryo and placenta for other prenatal tests (More? prenatal diagnosis).

The ultrasound technique can be used at any stage during pregnancy for fetal and placenta monitoring (More? Placenta Development | Placenta Abnormalities | Prenatal Diagnosis).

<html5media height="300" width="400">File:Ultrasound_Fetus_02.mp4</html5media>

The ultrasound movies can be viewed in two ways: Clicking either the movie image or "Page" text below the image opens a new page with both the movie and a more detailed text description of features. Embedded movies then play by clicking the play triangle icon lying over the movie image. Clicking on the "Play" link will open the MP4 movie version alone on a new page. Abnormal developmental ultrasound and features are listed on a separate page (More? abnormal ultrasound) all content is for educational use only.

Page | Play Movie shows a 12 week fetus in 3d in realtime (hence 4D).

Special thanks to Dr Andrew McLennan, Foetal Medicine Unit, Royal North Shore Hospital for many of the original video materials.

| Abnormal Ultrasound

Some Recent Findings

Cut-off value for normal nuchal translucency evaluated by chromosomal microarray analysis "An association between isolated, increased nuchal translucency thickness and pathogenic chromosomal microarray analysis (CMA) has been reported. A recent meta-analysis reported that most studies used a 3.5 mm cut-off value. Considering nuchal translucency distribution and the commonly accepted 5% false positive rate in maternal serum screening, nuchal translucency cut-off levels should be reconsidered. This study evaluated the unique contribution of CMA to the investigation of foetuses with mildly increased nuchal translucency (NT) thickness of 3.0-3.4 mm."

More recent papers

This table allows an automated computer search of the external PubMed database using the listed "Search term" text link. This search now requires a manual link as the original PubMed extension has been disabled. The displayed list of references do not reflect any editorial selection of material based on content or relevance. References also appear on this list based upon the date of the actual page viewing. References listed on the rest of the content page and the associated discussion page (listed under the publication year sub-headings) do include some editorial selection based upon both relevance and availability. More? References | Discussion Page | Journal Searches | 2019 References | 2020 References Search term: Nuchal Translucency <pubmed limit=5>Nuchal Translucency</pubmed>

Neural

Neural
‎‎Dandy-Walker Page | Play	‎‎Spina Bifida Page | Play

Anencephaly ultrasound

Ultrasound Gestational Age

The following table is based upon Australian data from ultrasound measurements of Crown Rump Length (CRL).

Note that Gestational Age GA differs from fertilisation age by about 2 weeks.

Gestational Age and Crown-Rump Length (measured by ultrasound)

Gestational Age GA (week.day) Crown-Rump Length (CRL) 5.2 1 5.3 2 5.4 3 55 3 5.6 4 6 4 6.1 5 6.2 6 6.3 7 6.4 8 6.5 9 6.6 10 7 11 7.1 11 7.2 12 7.3 12 7.4 13 7.5 14 7.6 15 8 17 8.1 18 8.2 19 8.3 20 8.4 21 8.5 22 8.6 22 9 23 9.1 24 9.2 26 9.3 27 9.4 28 9.5 29 9.6 31 10 34 10.1 36 10.2 37 10.3 38 10.4 39 10.5 39 10.6 40 11 44 11.1 45 11.2 47 11.3 48 11.4 52 11.5 55 11.6 56 12 57 12.1 58 12.2 60 12.3 61 12.4 63 12.5 64 12.6 65 13 68 13.1 70 13.2 72 13.3 74 113.4 76 135 77 13.6 80 14 81 14.1 84 14.2 85 14.3 86 14.4 87 Reference Table adapted from Westerway (2015) PDF and <pubmed>11065037</pubmed>

Fertilization and Gestational Age - Crown-Rump Length (ultrasound)

Fertilization Age (days) Gestational Age GA (week.day) Crown-Rump Length (mm) 37 5.2 1 38 5.3 2 39 5.4 3 40 55 3 41 5.6 4 42    Week 4 6 4 43 6.1 5 44 6.2 6 45 6.3 7 46 6.4 8 47 6.5 9 48 6.6 10 49    Week 5 7 11 50 7.1 11 51 7.2 12 52 7.3 12 53 7.4 13 54 7.5 14 55 7.6 15 56    Week 6 8 17 57 8.1 18 58 8.2 19 59 8.3 20 60 8.4 21 61 8.5 22 62 8.6 22 63    Week 7 9 23 64 9.1 24 65 9.2 26 66 9.3 27 67 9.4 28 68 9.5 29 69 9.6 31 70    Week 8 10 34 71 10.1 36 72 10.2 37 73 10.3 38 74 10.4 39 75 10.5 39 76 10.6 40 77    Week 9 11 44 78 11.1 45 79 11.2 47 80 11.3 48 81 11.4 52 82 11.5 55 83 11.6 56 84    Week 10 12 57 85 12.1 58 86 12.2 60 87 12.3 61 88 12.4 63 89 12.5 64 90 12.6 65 91    Week 11 13 68 92 13.1 70 93 13.2 72 94 13.3 74 95 113.4 76 96 135 77 97 13.6 80 98    Week 12 14 81 99 14.1 84 100 14.2 85 101 14.3 86 102 14.4 87 Reference: Table data measured by ultrasound, adapted from Westerway (2015) PDF and Links: ultrasound | Fetal Development

CRL-GA TableFA-GA-CRL

Additional Images

• 

  Ultrasound uterine and ovarian vascularity

References

Journals

• Journal of Ultrasound in Medicine published by the American Institute of Ultrasound in Medicine.

Books

Molecular Imaging and Contrast Agent Database (MICAD) NBK5330 | PMID:20641179

Articles

<pubmed>24518917</pubmed> <pubmed>22660228</pubmed>

Search PubMed

Search PubMed: Ultrasound prenatal diagnosis | Ultrasound

Prenatal Diagnosis Terms

• ART - Assisted Reproductive Technology a general term to describe all the clinical techniques used to aid fertility.

• blastomere biopsy - An ART preimplantation genetic diagnosis technique carried out at cleavage stage (day 3), excluding poor quality embryos, detects chromosomal abnormalities of both maternal and paternal origin. May not detect cellular mosaicism in the embryo.

• blastocyst biopsy - An ART preimplantation genetic diagnosis technique carried out at blastocyst stage (day 4-5), removes several trophoblast (trophoderm) cells, detects chromosomal abnormalities of both maternal and paternal origin and may detect cellular mosaicism.

• cell-free fetal deoxyribonucleic acid - (cfDNA) refers to fetal DNA circulating and isolated from the plasma portion of maternal blood. Can be performed from GA 10 weeks as a first-tier test or as a second-tier test, with women with increased probability on combined first trimester screening offered cfDNA or diagnostic testing.

• false negative rate - The proportion of pregnancies that will test negative given that the congenital anomaly is present.

• false positive rate - The proportion of pregnancies that will test positive given that the congenital anomaly is absent.

• free β human chorionic gonadotrophin - beta-hCG subunit of hCG used as a diagnostic marker for: early detection of pregnancy, Trisomy 21, spontaneous abortion, ectopic pregnancy, hydatidiform mole or choriocarcinoma.

• multiples of the median - (MoM) A multiple of the median is a measure of how far an individual test result deviates from the median and is used to report the results of medical screening tests, particularly where the results of the individual tests are highly variable.

• negative predictive value - The probability that a congenital anomaly is absent given that the prenatal screening test is negative.

• Non-Invasive Prenatal Testing - (NIPT) could refer to ultrasound or other imaging techniques, but more frequently used to describe analysis of cell-free fetal DNA circulating in maternal blood.

• polar body biopsy - (PB biopsy) An ART preimplantation genetic diagnosis technique that removes either the first or second polar body from the zygote. As these are generated by oocyte meiosis they detects chromosomal abnormalities only on the female genetics.

• positive predictive value - The probability that a congenital anomaly is present given that the prenatal screening test is positive.

• pre-implantation genetic diagnosis - (PGD, pre-implantation genetic screening) a diagnostic procedure for embryos produced through Assisted Reproductive Technology (ART, in vitro fertilisation, IVF) for genetic diseases that would generate developmental abnormalities or serious postnatal diseases.

• prenatal screening sensitivity - (detection rate) The probability of testing positive on a prenatal screening test if the congenital anomaly is present.

• prenatal screening specificity - The probability of testing negative on a prenatal screening test if the congenital anomaly is absent.

• quadruple test (maternal serum testing of a-fetoprotein Template:AFP, free B-hCG or total hCG, unconjugated estriol, and inhibin A) is a fetal chromosomal anomaly test usually carried out later in pregnancy (GA 14 to 20 weeks).

• single nucleotide polymorphisms - (SNPs) the variation in a single DNA nucleotide that occurs at a specific position in the genome.

• triple test - (maternal serum testing of a-fetoprotein Template:AFP, free B-hCG or total hCG, and unconjugated estriol) is a fetal chromosomal anomaly test usually carried out later in pregnancy (GA 14 to 20 weeks).

Terms

Ultrasound

• Biparietal diameter - (BPD) used to determine fetal age and normal development (small/large/abnormal) parameters. Measured as the diameter between the 2 sides of the head, measurements after 13 weeks (2.4 cm) to term (9.5 cm).

• cerebroplacental ratio - (CPR) a doppler ultrasound measurement calculated as the simple ratio between the middle cerebral artery pulsatility index (MCA‐PI) and the {{placenta]]l artery pulsatility index (UA‐PI). Fetuses with an abnormal ratio are thought to be a predictor of adverse pregnancy outcome such as: small for gestational age, abnormal fetal heart rate pattern, meconium stained liquor, low Apgar score, and acidosis at birth. PMID 28216258

• Crown-Rump Length - (CRL) measurement used in embryology to more accurately stage the early embryo and fetus. Measured from the curvature at the top (crown) to the curvature at the bottom (rump) of the "C-shaped" early embryo. Used in clinical ultrasound as a measurement between the periods of 7 to 13 weeks as an accurate estimation of the gestational age GA.

• DICOM - (ISO standard 12052:2006) Acronym for Digital Imaging and Communications in Medicine, a clinical standard for handling, storing, printing, and transmitting imaging information.

• Femur length - (FL) is used to determine fetal age and normal development (small/large/abnormal) parameters. The femur is the longest bone in the body and measurements and reflects the longitudinal growth of the fetus (approximately 14 weeks 1.5 cm - term 7.8 cm). It is one of the four typical ultrasound assessments of fetal size and age: Biparietal Diameter (BPD), |Head Circumference (HC), Abdominal Circumference (AC), and Femur Length (FL).

• Fetal size and age - typically measured using 4 ultrasound assessments: Biparietal Diameter (BPD), Head Circumference (HC), Abdominal Circumference (AC), and Femur Length (FL).

• Functional linear discriminant analysis - (FLDA) new growth assessment technique using serial measurements to discriminate between normal and abnormal fetal growth during 2nd and 3rd trimester.

• Head Circumference - (HC) Measured as an ellipse in a horizontal section at the level of the thalamus and the cavum septi pellucidi. 2nd trimester Fetal head growth

• Gestational sac - (GS) size formed initially by the chorionic cavity, after the embryonic period (week 8, GA W10) the amniotic cavity expands and fuses with the chorion. Measured by mean gestation sac diameter.

• inversion mode - an ultrasound processing method of volume analysis for the visualization of fluid-filled fetal structures such as; heart chambers, vessel lumen, stomach, gallbladder, renal pelvis, and the bladder. Post-processing inverts the gray scale of the volume voxels showing the normally anechoic structures in 3D or 4D renderings. This technique has been used to identify cardiac anomalies.

• Linear discriminant analysis - (LDA) to longitudinal data (James and Hastie, 2001)

• Mean gestation sac diameter - (MSD) = (length + height + width)/3. At week 3 (GAweek 5) MSD measures 2-3 mm. Normal MSD (in mm) + 30 = days of pregnancy.

• Mean yolk sac diameter - (MYD) can be used as marker for subsequent embryonic death or abnormalities (PMID 22215774).

• Spatiotemporal image correlation (STIC) - an image acquisition method used mainly for fetal heart analysis. Requires two steps; an automatic volume sweep, then image data analysis according to spatial and temporal domain generating an online dynamic 3D image sequence.

• Transabdominal scan - the ultrasound probe is placed on the external abdomen wall to scan pelvic region structures, conceptus and placenta. Also used to guide prenatal diagnostic techniques of chorionic villus sampling and amniocentesis.

• Transvaginal scan - (TVS) the ultrasound probe is placed inside the vagina and scans for female genital (uterus, ovary) and ectopic pregnancy.

• Termination of pregnancy - (TOP)

External Links

External Links Notice - The dynamic nature of the internet may mean that some of these listed links may no longer function. If the link no longer works search the web with the link text or name. Links to any external commercial sites are provided for information purposes only and should never be considered an endorsement. UNSW Embryology is provided as an educational resource with no clinical information or commercial affiliation.

• Australian Society for Ultrasound Medicine - Guidelines For The Mid Trimester Obstetric Scan PDF (2005)
• American Registry for Diagnostic Medical Sonography - ARDMS Resources for Students and Educators

Glossary Links

Glossary: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Numbers | Symbols | Term Link

---

Cite this page: Hill, M.A. (2024, April 26) Embryology Ultrasound - Nuchal Translucency. Retrieved from https://embryology.med.unsw.edu.au/embryology/index.php/Ultrasound_-_Nuchal_Translucency

What Links Here?

© Dr Mark Hill 2024, UNSW Embryology ISBN: 978 0 7334 2609 4 - UNSW CRICOS Provider Code No. 00098G